Emerging evidence of the impact of kidney disease on drug metabolism and transport

被引：205

作者：

Nolin, T. D. ^{[4
,5
]}

Naud, J. ^{[1
,2
,3
]}

Leblond, F. A. ^{[1
,2
]}

Pichette, V. ^{[1
,2
,3
]}

机构：

[1] Hop Maison Neuve Rosemont, Ctr Rech, Montreal, PQ H1T 2M4, Canada

[2] Hop Maison Neuve Rosemont, Serv Nephrol, Montreal, PQ H1T 2M4, Canada

[3] Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada

[4] Maine Med Ctr, Res Inst, Ctr Clin & Translat Res, Scarborough, ME USA

[5] Maine Med Ctr, Dept Med, Div Nephrol & Transplantat, Portland, ME 04102 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2008年 / 83卷 / 06期

关键词：

D O I：

10.1038/clpt.2008.59

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Several lines of emerging evidence indicate that kidney disease differentially affects uptake and efflux transporters and metabolic enzymes in the liver and gastrointestinal (GI) tract, and uremic toxins have been implicated as the cause. In patients with kidney disease, even drugs that are eliminated by nonrenal transport and metabolism could lead to important unintended consequences if they are administered without dose adjustment for reduced renal function. This is particularly so in the case of drugs with narrow therapeutic windows and may translate into clinically significant variations in exposure and response.

引用

页码：898 / 903

页数：6

共 38 条

[31] Effects of renal failure on drug transport and metabolism
Sun, H
Frassetto, L
Benet, LZ
[J]. PHARMACOLOGY & THERAPEUTICS, 2006, 109 (1-2) : 1 - 11
[32] Effects of uremic toxins on hepatic uptake and metabolism of erythromycin
Sun, H
Huang, Y
Frassetto, L
Benet, LZ
[J]. DRUG METABOLISM AND DISPOSITION, 2004, 32 (11) : 1239 - 1246
[33] Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites
Turpeinen, Miia
Koivuviita, Niina
Tolonen, Ari
Reponen, Petri
Lundgren, Stefan
Miettunen, Jouko
Metsarinne, Kaj
Rane, Anders
Pelkonen, Olavi
Laine, Kari
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 64 (02) : 165 - 173
[34] *US DHHS FDA CTR D, 1998, GUID IND PHARM PAT I
[35] Pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance
Vormfelde, SV
Mück, W
Freudenthaler, SM
Heyen, P
Schmage, N
Kuhlmann, J
Müller, GA
Gundert-Remy, UM
Gleiter, CH
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (02) : 147 - 154
[36] Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system
Wu, CY
Benet, LZ
[J]. PHARMACEUTICAL RESEARCH, 2005, 22 (01) : 11 - 23
[37] Effect of experimental renal failure on the pharmacokinetics of losartan in rats
Yoshitani, T
Yagi, H
Inotsume, N
Yasuhara, M
[J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2002, 25 (08) : 1077 - 1083
[38] Effect of chronic renal insufficiency on hepatic and renal UDP-glucuronyltransferases in rats
Yu, CH
Ritter, JK
Krieg, RJ
Rege, B
Karnes, TH
Sarkar, MA
[J]. DRUG METABOLISM AND DISPOSITION, 2006, 34 (04) : 621 - 627

← 1 2 3 4 →